



11 Publication number:

0 508 427 A3

(12)

EUROPEAN PATENT APPLICATION

21 Application number: 92106172.7

Application number. 92106172.

2 Date of filing: 09.04.92

(s) Int. Cl.5: **G01N 33/569**, //G01N33/571, C07K15/00

Priority: 09.04.91 JP 76267/91

43 Date of publication of application: 14.10.92 Bulletin 92/42

Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU MC
NL PT SE

Date of deferred publication of the search report:

05.05.93 Bulletin 93/18

Applicant: Yanagi, Kazuo 5-12, Wakaba, Kukisaki-cho Inashiki-gun, Ibaraki(JP) Applicant: MOCHIDA PHARMACEUTICAL CO.,

LTD.

7, Yotsuya 1- chome Shinjuku- ku Tokyo 160(JP)

Inventor: Yanagi, Kazuo 5~12, Wakaba, Kukisaki- cho Inashiki- gun, Ibaraki(JP) Inventor: Inoue, Naoki 31-16-406, Honcho Wako- shi, Saitama(JP) Inventor: Harada, Shizuko 1-1-14, Yutaka- cho, Shinagawa

1-1-14, Yutaka-cho, Shinagawa-ku Tokyo(JP)

Representative: Patentanwälte Grünecker, Kinkeldey, Stockmalr & Partner Maximilianstrasse 58 W-8000 München 22 (DE)


- Method and kit for measuring anti-EBNA antibodies.
- This invention provides a simple immunoassay system and a measuring kit for use in the measure ment of anti EBNA antibodies, in which recom binant type EBNA proteins are used. The anti EBNA antibody measuring kit is useful for the in dividual measurement of anti EBNA 1 antibodies, anti EBNA 2 antibodies, anti EBNA 3 anti bodies, anti EBNA 4 antibodies, anti EBNA 5 antibodies and anti EBNA 6 antibodies.

Particularly, this invention provides a method for the measurement of anti-EBNA antibodies which comprises the steps of allowing anti-EBNA antibodies in a test sample to react with a recombinant type EBNA fusion protein immobilized on a support through an anti – β – galactosidase antibody, allowing the anti – EBNA antibodies to react with an enzyme – conjugated anti – EBNA antibody and measuring a signal (enzyme activity) generated from the conjugated enzyme contained in an immune complex formed by the above steps.

Also particularly, this invention provides an anti-EBNA antibody measuring kit in which an anti- β -galactosidase antibody and a recombinant type EBNA fusion protein are immobilized on a support through binding of the anti- β -galac-tosidase antibody to the support and binding of the recombinant type EBNA fusion protein to the anti- β -galactosidase antibody.

EP 0 508 427 A3

Fig. 1





EUROPEAN SEARCH REPORT

Application Number

EP 92 10 6172 **7** PAGE1

	DOCUMENTS CONSI	DERED TO BE RELEVAN	TI I		
Category	Citation of document with it of relevant pa	ndication, where appropriate,	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. CL5)	
X	EP-A-0 281 803 (BEH AKTIENGESELLSCHAFT) * the whole documen	RINGWERKE	1-54	G01N33/569 //G01N33/571 //C07K15/00	
X	WO-A-8 601 210 (SCR RESEARCH FOUNDATION * page 6 - page 7 * * page 12 * * page 13, line 33 * page 14, line 29 * page 35, line 7 -) - page 14, line 8 * - page 15. line 6 *	1-4,11, 21-23, 26,39,40		
Y	* page 47 - page 50	*****	5-10, 12-20, 24,25, 27-38, 41-58		
Y	KEMENY ET AL. (EDS. solid phase immunoa practical aspects' 1988 , JOHN WILEY &	ssays. Theoretical and	5-10, 12-20, 24,25, 27-38, 41-58	TECHNICAL FIELDS SEARCHED (tot. Cl.5)	
	Kemeny et al. 'An i * page 1 - page 29;	ntroduction to ELISA' figures 1-6 *		GO1N	
	JOURNAL OF INFECTION vol. 156, no. 1, Ju pages 26 - 35 MILLER ET AL. 'Selet to a component of El patients with chronivirus infection' * page 27, right co column *	1,2,59, 60			
D,Y	ee immi	-/	55-58		
	The present search report has be	en drawn up for all claims			
	Place of search	Date of completion of the search	' 	Examinar	
BERLIN		16 FEBRUARY 1993	CEDER O.		
K: particularly relevant if taken alone Y: particularly relevant if combined with another Accument of the same category L: door A: technological hackground			ory or principle underlying the invention filer patent document, but published on, or or the filing date cument cited in the application cument cited for other reasons waber of the same patent family, corresponding		

EPO FORM 15th ed.e2 (Posts)

EP 92 10 6172 PAGE2

		IDERED TO BE RELEVAN indication, where appropriate,	Relevant	CLASSIFICATION OF THE
Category	of relevant p		to claim	APPLICATION (Int. Cl.5)
D,X	SCIENCES vol. 81, no. 14, Ju pages 4373 - 4377 HEARING ET AL. 'Ide	sequences that encode a cressed in latently es'	1,2,11,21,23	
D,X	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES vol. 84, no. 2, January 1987, WASHINGTON DC pages 570 - 574 HENLE ET AL. 'Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection' * page 571, left column *		1,2	
D,A	page 0/2, 10/10 00		23,55, 56,59,60	TECHNICAL FIELDS SEARCHED (Int. Cl.5)
D,X	INTERNATIONAL JOURN vol. 40, 1987, NEW pages 349 - 353 SEIGNEURIN ET AL. 'against the Epstein nuclear antigen2 (Egroups of individua * page 350, left co	1,2		
D,A		-/	23,55,56,59,60	
	The present search report has i	ocen drawn up for all claims		
	Place of search	Date of completion of the search		Bantor
8	BERLIN	16 FEBRUARY 1993	'	CEDER O.
X : part Y : part doc A : tech : non	CATEGORY OF CITED DOCUME ticularly relevant if taken alone ticularly relevant if combined with an unemt of the same category anological background -written disclosure rusediate document	E : earlier patent do after the filing d	cument, but publicate in the application or other reasons	shed on, or



EUROPEAN SEARCH REPORT

Application Number

EP 92 10 6172 PAGE3

				PAGE3		
		DERED TO BE RELEVA				
Category	Citation of document with in of relevant pas		Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)		
X	DATABASE WPIL Week 8926, Derwent Publication: AN 89-189421 & JP-A-1 128 788 (C/May 1989 * abstract *	s Ltd., London, GB; ALPIS SHOKUHIN KOG) 22	1,2	•		
A	WO-A-9 001 495 (SCR) RESEARCH FOUNDATION					
E	DATABASE WPIL Week 9238, Derwent Publications AN 92-313682 & JP-A-4 221 399 (MCAugust 1992 * abstract *	•	1-4			
:				TECHNICAL FIELDS SEARCHED (lat. Cl.5)		
	The present search report has be	en drawn up for all claims				
	Place of search	Date of completion of the search		Product		
E	BERLIN	16 FEBRUARY 1993		CEDER O.		
X: part Y: part docr	CATEGORY OF CITED DOCUMEN icularly relevant if taken alone icularly relevant if combined with anot ment of the same category nolocical backwround	E : earlier palent e after the filing her D : éocument cite L : éocument citeé	in the application for other reasons	shed on, or		
A : technological background O : non-written disclosure P : intermediate document			& : member of the same patent family, corresponding document			

PORM 1500 GLAZ (PO404